Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Retinal macrophage-like cell activation and ganglion cell layer thinning are associated with disability and MRI lesion burden in multiple sclerosis.

PloS one·2026
Same author

Should autologous HSCT be a first-line option in highly active MS? No.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Cerebrovascular Manifestations of Neurosarcoidosis - An Overview.

Vascular health and risk management·2026
Same author

Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2026

Related Experiment Video

Updated: Jun 15, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Neuromyelitis optica - an update: 2007-2009.

Anu Jacob1

  • 1The Walton Centre for Neurology and Neurosurgery, Liverpool, L97LJ, United Kingdom.

Annals of Indian Academy of Neurology
|February 26, 2010
PubMed
Summary

Neuromyelitis optica (NMO) research has advanced significantly, particularly regarding the aquaporin-4 antibody. New findings clarify NMO's epidemiology, pathogenesis, and treatment strategies, including effective therapies like rituximab.

Keywords:
Aquaporinmultiple sclerosismyelitisneuromyelitis optica

More Related Videos

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Related Experiment Videos

Last Updated: Jun 15, 2026

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients
12:23

Dynamic Visual Tests to Identify and Quantify Visual Damage and Repair Following Demyelination in Optic Neuritis Patients

Published on: April 14, 2014

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
09:29

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4

Published on: August 21, 2017

Area of Science:

  • Neuroimmunology
  • Demyelinating diseases of the central nervous system

Background:

  • Neuromyelitis optica (NMO) is a severe inflammatory demyelinating disorder affecting the central nervous system.
  • Recent discoveries, especially the NMO IgG /aquaporin-4 antibody, have revitalized NMO research.
  • This review updates significant advancements in NMO, focusing on developments from the last two years.

Purpose of the Study:

  • To summarize key recent advances in neuromyelitis optica research.
  • To provide updated insights into the epidemiology, pathogenesis, and management of NMO.
  • To supplement previous reviews on neuromyelitis optica.

Main Methods:

  • Review of recent epidemiological studies on NMO incidence and prevalence.
  • Analysis of research on aquaporin-4 gene mutations and antibody effects on astrocytes.
  • Examination of the roles of excitatory amino acid transporter type 2 and glutamate in NMO pathogenesis.
  • Assessment of the antigenic requirements for aquaporin-4.
  • Investigation of aquaporin-4 antibody presence in associated conditions like cancer and PRES.
  • Evaluation of antibody monitoring and therapeutic effectiveness of rituximab and mycophenolate.

Main Results:

  • Epidemiological data now provide estimates for NMO incidence and prevalence.
  • Aquaporin-4 gene mutations have been identified, and its role in astrocyte pathology is better understood.
  • The requirement of aquaporin-4 in orthogonal arrays for antigenicity is recognized.
  • Aquaporin-4 antibodies are found in patients with cancer and posterior reversible encephalopathy syndrome (PRES).
  • Rituximab and mycophenolate demonstrate effectiveness in preventing NMO relapses.

Conclusions:

  • Significant progress has been made in understanding neuromyelitis optica pathogenesis and epidemiology.
  • The aquaporin-4 antibody is a crucial biomarker and potential therapeutic target in NMO.
  • Current treatments like rituximab and mycophenolate show promise in managing NMO relapses.